Skip to Content
Merck
All Photos(1)

Documents

1625009

USP

Sulfadiazine

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4-Amino-N-(2-pyrimidinyl)benzenesulfonamide, N1-(Pyrimidin-2-yl)sulfanilamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H10N4O2S
CAS Number:
68-35-9
Molecular Weight:
250.28
Beilstein:
6733588
MDL number:
MFCD00006065
UNSPSC Code:
41116107
PubChem Substance ID:
329751168
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

sulfadiazine

manufacturer/tradename

USP

mp

253 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

InChI key

SEEPANYCNGTZFQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sulfadiazine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Silver Sulfadiazine Cream
  • Sulfadiazine
  • Sulfadiazine Sodium
  • Sulfadiazine Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1633506

Sulfanilic acid, United States Pharmacopeia (USP) Reference Standard

1612608

Silver sulfadiazine, United States Pharmacopeia (USP) Reference Standard

S1800000

Sulfadiazine, European Pharmacopoeia (EP) Reference Standard

Y0001469

Sulfadiazine impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001480

Sulfadiazine for identification of impurity F, European Pharmacopoeia (EP) Reference Standard

Y0001462

Acetylsulfadiazine, European Pharmacopoeia (EP) Reference Standard

PHR1419

Sulfanilic Acid, Pharmaceutical Secondary Standard; Certified Reference Material

BP312

Sulfadiazine, British Pharmacopoeia (BP) Reference Standard

PHR2654

Silver Sulfadiazine, Pharmaceutical Secondary Standard; Certified Reference Material

Signal Word

Warning

Hazard Statements

H302,H361d,H411

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K Becker et al.
Medicine, 75(4), 185-194 (1996-07-01)
We performed a computerized search on sulfadiazine-associated nephrotoxicity reported in human immunodefiency virus (HIV)-infected patients in the international literature. Including an original case report, we summarized 35 acquired immunodefiency syndrome (AIDS) patients from 1987 to 1995 in an analysis comparing
Charlotte Catalano-Pons et al.
Pediatric nephrology (Berlin, Germany), 19(8), 928-931 (2004-06-19)
Sulfadiazine-associated urinary calculi have been described in HIV-positive adult patients but rarely in children. We report two pediatric cases of sulfadiazine-induced nephrolithiasis and review 45 adult cases from the literature. One had a hyper-IgM syndrome and was treated with sulfadiazine
D I Simon et al.
Archives of internal medicine, 150(11), 2379-2384 (1990-11-01)
Toxoplasma gondii encephalitis is an important opportunistic infection in the acquired immunodeficiency syndrome, estimated to occur in 20,000 to 40,000 patients with acquired immunodeficiency syndrome in the United States by 1991. The combination of sulfadiazine and pyrimethamine is regarded as
U Kronawitter et al.
Deutsche medizinische Wochenschrift (1946), 118(46), 1683-1686 (1993-11-19)
A 45-year-old man with AIDS was treated for a recurrence of cerebral toxoplasmosis with sulphadiazine, 4 g, and pyrimethamine, 75 mg, daily. Owing to a lack of appetite and dysphagia he drank rather little water during the first week of
L M Upton et al.
Antimicrobial agents and chemotherapy, 59(1), 490-497 (2014-11-12)
To achieve malarial elimination, we must employ interventions that reduce the exposure of human populations to infectious mosquitoes. To this end, numerous antimalarial drugs are under assessment in a variety of transmission-blocking assays which fail to measure the single crucial
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service